229 related articles for article (PubMed ID: 8099332)
1. Characterisation of a chimeric hD3/D2 dopamine receptor expressed in CHO cells.
McAllister G; Knowles MR; Patel S; Marwood R; Emms F; Seabrook GR; Graziano M; Borkowski D; Hey PJ; Freedman SB
FEBS Lett; 1993 Jun; 324(1):81-6. PubMed ID: 8099332
[TBL] [Abstract][Full Text] [Related]
2. Expression and pharmacological characterization of the human D3 dopamine receptor.
Freedman SB; Patel S; Marwood R; Emms F; Seabrook GR; Knowles MR; McAllister G
J Pharmacol Exp Ther; 1994 Jan; 268(1):417-26. PubMed ID: 8301582
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
Van Leeuwen DH; Eisenstein J; O'Malley K; MacKenzie RG
Mol Pharmacol; 1995 Aug; 48(2):344-51. PubMed ID: 7651368
[TBL] [Abstract][Full Text] [Related]
4. Chimeric D2/D3 dopamine receptor coupling to adenylyl cyclase.
Lachowicz JE; Sibley DR
Biochem Biophys Res Commun; 1997 Aug; 237(2):394-9. PubMed ID: 9268722
[TBL] [Abstract][Full Text] [Related]
5. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.
Chio CL; Lajiness ME; Huff RM
Mol Pharmacol; 1994 Jan; 45(1):51-60. PubMed ID: 8302280
[TBL] [Abstract][Full Text] [Related]
6. G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
Newman-Tancredi A; Cussac D; Audinot V; Pasteau V; Gavaudan S; Millan MJ
Mol Pharmacol; 1999 Mar; 55(3):564-74. PubMed ID: 10051542
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
MacKenzie RG; VanLeeuwen D; Pugsley TA; Shih YH; Demattos S; Tang L; Todd RD; O'Malley KL
Eur J Pharmacol; 1994 Jan; 266(1):79-85. PubMed ID: 7907989
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells.
Gardner B; Hall DA; Strange PG
Br J Pharmacol; 1996 Jul; 118(6):1544-50. PubMed ID: 8832084
[TBL] [Abstract][Full Text] [Related]
9. Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors.
Levant B; Grigoriadis DE; De Souza EB
Eur J Pharmacol; 1995 May; 278(3):243-7. PubMed ID: 7589161
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Sokoloff P; Andrieux M; Besançon R; Pilon C; Martres MP; Giros B; Schwartz JC
Eur J Pharmacol; 1992 Apr; 225(4):331-7. PubMed ID: 1354163
[TBL] [Abstract][Full Text] [Related]
11. Chimeric D1/D2 dopamine receptors. Distinct determinants of selective efficacy, potency, and signal transduction.
Kozell LB; Machida CA; Neve RL; Neve KA
J Biol Chem; 1994 Dec; 269(48):30299-306. PubMed ID: 7982941
[TBL] [Abstract][Full Text] [Related]
12. High affinity agonist binding to the dopamine D3 receptor: chimeric receptors delineate a role for intracellular domains.
Robinson SW; Jarvie KR; Caron MG
Mol Pharmacol; 1994 Aug; 46(2):352-6. PubMed ID: 7915820
[TBL] [Abstract][Full Text] [Related]
13. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
Perachon S; Schwartz JC; Sokoloff P
Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
[TBL] [Abstract][Full Text] [Related]
14. Coupling of dopamine receptors to G proteins: studies with chimeric D2/D3 dopamine receptors.
Ilani T; Fishburn CS; Levavi-Sivan B; Carmon S; Raveh L; Fuchs S
Cell Mol Neurobiol; 2002 Feb; 22(1):47-56. PubMed ID: 12064517
[TBL] [Abstract][Full Text] [Related]
15. Effects of reciprocal chimeras between the C-terminal portion of third intracellular loops of the human dopamine D2 and D3 receptors.
Filteau F; Veilleux F; Lévesque D
FEBS Lett; 1999 Mar; 447(2-3):251-6. PubMed ID: 10214956
[TBL] [Abstract][Full Text] [Related]
16. The human dopamine D2(Longer) receptor has a high-affinity state and inhibits adenylyl cyclase.
Liu IS; George SR; Seeman P
Brain Res Mol Brain Res; 2000 May; 77(2):281-4. PubMed ID: 10837924
[TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of adenylate cyclase induced by a dopamine D2 receptor mutant: inverse agonism by D2 receptor antagonists.
Bullock CM; Li C; Li M; Bermak JC; Zhou QY
Prog Neuropsychopharmacol Biol Psychiatry; 2001 Oct; 25(7):1387-402. PubMed ID: 11513354
[TBL] [Abstract][Full Text] [Related]
19. Selection of alternative G-mediated signaling pathways at the dopamine D2 receptor by protein kinase C.
Di Marzo V; Vial D; Sokoloff P; Schwartz JC; Piomelli D
J Neurosci; 1993 Nov; 13(11):4846-53. PubMed ID: 7693893
[TBL] [Abstract][Full Text] [Related]
20. Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells.
Vanhauwe JF; Ercken M; van de Wiel D; Jurzak M; Leysen JE
Psychopharmacology (Berl); 2000 Jul; 150(4):383-90. PubMed ID: 10958079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
